Karolinska Institutet
Edit

Karolinska Institutet

https://ki.se/
Last activity: 16.09.2025
Active
Categories: EdTechFinTechHealthTechHumanInfrastructureMedTechNewsResearchTrainingUniversity
Karolinska Institutet is one of the world´s leading medical universities. Our mission is to contribute to the improvement of human health through research and education. Karolinska Institutet accounts for over 40 per cent of the medical academic research conducted in Sweden and offers the country´s broadest range of education in medicine and health sciences. Since 1901 the Nobel Assembly at Karolinska Institutet has selected the Nobel laureates in Physiology or Medicine. Karolinska Institutet was founded by King Karl XIII in 1810 as an "academy for the training of skilled army surgeons"​. Today, Karolinska Institutet is a modern medical university and one of the foremost in the world. With our close relationship to the clinical milieu, a well established infrastructure and a stable financial situation, Karolinska Institutet has excellent prerequisites for sustaining high quality research and education.
Followers
101.08K
Website visits
1.7M /mo.
Mentions
263
Location: Sweden, Stockholm
Employees: 5001-10000
Founded date: 1810

Mentions in press and media 263

DateTitleDescription
16.09.2025AnaCardio Announces Completion of Target Enrollment in Phase 2a Study of AC01 in Heart Failure; Results Expected Year-end 2025AnaCardio Announces Completion of Target Enrollment in Phase 2a Study of AC01 in Heart Failure; Results Expected Year-end 2025 Tue, Sep 16, 2025 09:00 CET Report this content Stockholm, Sweden, September 16, 2025 – AnaCardio, a clinical-sta...
10.09.2025Main owners strengthen their position in SciBaseMain owners strengthen their position in SciBase Wed, Sep 10, 2025 10:15 CET Report this content SWEDEN – September 10, 2025 - SciBase Holding AB ("SciBase") [STO: SCIB], a leader in AI-based devices for detection and prevention i...
09.09.2025Oxcia compounds demonstrate antiviral activityOxcia compounds demonstrate antiviral activity Tue, Sep 09, 2025 10:38 CET Report this content In a pre-clinical study, OXC-201 (TH5487) and its analogue TH6744 show antiviral activity and reduce ZIKV (Zika virus)-induced microcephaly in a ...
04.09.2025Doctoral thesis to be defended today: Title ‘’Tumor response mechanisms and treatment effects of alpha1-oleate’’Doctoral thesis to be defended today: Title ‘’Tumor response mechanisms and treatment effects of alpha1-oleate’’ Thu, Sep 04, 2025 10:38 CET Report this content Hamlet BioPharma, the pharmaceutical company, specializing in the development o...
02.09.2025AnaCardio strengthens leadership team with appointment of Philipp Mathieu as Chief Financial OfficerAnaCardio strengthens leadership team with appointment of Philipp Mathieu as Chief Financial Officer Tue, Sep 02, 2025 09:00 CET Report this content Stockholm, Sweden, September 2, 2025 - AnaCardio, a Swedish clinical-stage biopharmaceutica...
28.08.2025Proton center in South Korea selects RayStation and RayCareProton center in South Korea selects RayStation and RayCare Thu, Aug 28, 2025 09:45 CET Report this content RaySearch Laboratories AB (publ) is pleased to announce that Keimyung University Dongsan Medical Center (DSMC) in South Korea has se...
26.08.2025Neogap appoints leading international cell therapy expert to its BoardNeogap appoints leading international cell therapy expert to its Board Tue, Aug 26, 2025 06:30 CET Report this content Neogap Therapeutics AB, a Swedish clinical-stage biotechnology company developing personalised immunotherapy for cancer t...
26.08.2025EMA approves ODD for OXC-101 in AMLEMA approves ODD for OXC-101 in AML Tue, Aug 26, 2025 10:00 CET Report this content Earlier this spring, Oxcia's drug candidate OXC-101 received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for the treatment ...
19.08.2025Interim reportInterim report Tue, Aug 19, 2025 08:00 CET Report this content January 1 – June 30, 2025 The second quarter in figures Net sales were TSEK 8,791 (6,641), +32%, cleared for currency effects +40%. The loss after tax was TSEK 26,589 (15,050). ...
18.08.2025Intervacc’s distribution partner Dechra launches Strangvac in Spain, Portugal and SloveniaIntervacc’s distribution partner Dechra launches Strangvac in Spain, Portugal and Slovenia Mon, Aug 18, 2025 13:00 CET Report this content Intervacc AB (publ) announces today that its European distribution partner, Dechra Pharmaceuticals PL...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In